{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:28:20Z","timestamp":1782178100801,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000888","name":"W. M. Keck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40265-021-01636-5","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T10:02:47Z","timestamp":1638352967000},"page":"2081-2089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-352X","authenticated-orcid":false,"given":"Shelley N.","family":"Facente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3203-4590","authenticated-orcid":false,"given":"Angela M.","family":"Reiersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0471-9368","authenticated-orcid":false,"given":"Eric J.","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4715-0060","authenticated-orcid":false,"given":"David R.","family":"Boulware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-7364","authenticated-orcid":false,"given":"Jeffrey D.","family":"Klausner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"issue":"22","key":"1636_CR1","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","volume":"324","author":"EJ Lenze","year":"2020","unstructured":"Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292\u2013300. https:\/\/doi.org\/10.1001\/jama.2020.22760.","journal-title":"JAMA"},{"issue":"10239","key":"1636_CR2","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","volume":"395","author":"MJ Cummings","year":"2020","unstructured":"Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(20)31189-2.","journal-title":"Lancet"},{"issue":"7825","key":"1636_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/d41586-020-02598-6","volume":"585","author":"M Marshall","year":"2020","unstructured":"Marshall M. The lasting misery of coronavirus long-haulers. Nature. 2020;585(7825):339\u201341. https:\/\/doi.org\/10.1038\/d41586-020-02598-6.","journal-title":"Nature"},{"key":"1636_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.19719","author":"C Del Rio","year":"2020","unstructured":"Del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.19719.","journal-title":"JAMA"},{"issue":"21","key":"1636_CR5","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2020.22813","volume":"324","author":"PS Kim","year":"2020","unstructured":"Kim PS, Read SW, Fauci AS. Therapy for early COVID-19: a critical need. JAMA. 2020;324(21):2149\u201350. https:\/\/doi.org\/10.1001\/jama.2020.22813.","journal-title":"JAMA"},{"key":"1636_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-020-01231-x","author":"K Hashimoto","year":"2021","unstructured":"Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021. https:\/\/doi.org\/10.1007\/s00406-020-01231-x.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1636_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe9403","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Hiatt J, Bouhaddou M, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020. https:\/\/doi.org\/10.1126\/science.abe9403.","journal-title":"Science"},{"issue":"1","key":"1636_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14728222.12.1.45","volume":"12","author":"T Hayashi","year":"2008","unstructured":"Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Expert Opin Ther Targets. 2008;12(1):45\u201358. https:\/\/doi.org\/10.1517\/14728222.12.1.45.","journal-title":"Expert Opin Ther Targets"},{"key":"1636_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-319-50174-1_11","volume":"964","author":"Y Albayrak","year":"2017","unstructured":"Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. Adv Exp Med Biol. 2017;964:153\u201361. https:\/\/doi.org\/10.1007\/978-3-319-50174-1_11.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1636_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jphs.2014.11.010","volume":"127","author":"K Hashimoto","year":"2015","unstructured":"Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci. 2015;127(1):6\u20139. https:\/\/doi.org\/10.1016\/j.jphs.2014.11.010.","journal-title":"J Pharmacol Sci"},{"key":"1636_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.expneurol.2014.12.019","volume":"265","author":"K Hashimoto","year":"2015","unstructured":"Hashimoto K. Targeting the sigma-1 receptor chaperone in the treatment of perinatal brain injury. Exp Neurol. 2015;265:118\u201321. https:\/\/doi.org\/10.1016\/j.expneurol.2014.12.019.","journal-title":"Exp Neurol"},{"key":"1636_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-020-00983-3","author":"S Couly","year":"2020","unstructured":"Couly S, Goguadze N, Yasui Y, et al. Knocking out sigma-1 receptors reveals diverse health problems. Cell Mol Neurobiol. 2020. https:\/\/doi.org\/10.1007\/s10571-020-00983-3.","journal-title":"Cell Mol Neurobiol"},{"key":"1636_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5266","author":"DA Rosen","year":"2019","unstructured":"Rosen DA, Seki SM, Fern\u00e1ndez-Casta\u00f1eda A, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aau5266.","journal-title":"Science Transl Med"},{"key":"1636_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","volume":"727","author":"T Ishima","year":"2014","unstructured":"Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167\u201373. https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.064.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1636_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2174\/157015908787386113","volume":"6","author":"EJ Cobos","year":"2008","unstructured":"Cobos EJ, Entrena JM, Nieto FR, Cend\u00e1n CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol. 2008;6(4):344\u201366. https:\/\/doi.org\/10.2174\/157015908787386113.","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"1636_CR16","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1124\/dmd.107.015131","volume":"35","author":"D Hallifax","year":"2007","unstructured":"Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab Dispos. 2007;35(8):1325\u201332. https:\/\/doi.org\/10.1124\/dmd.107.015131.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1636_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00004850-199400940-00001","volume":"9","author":"W Wagner","year":"1994","unstructured":"Wagner W, Zaborny BA, Gray TE. Fluvoxamine. A review of its safety profile in world-wide studies. Int Clin Psychopharmacol. 1994;9(4):223\u20137. https:\/\/doi.org\/10.1097\/00004850-199400940-00001.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"1636_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1517\/17425255.2015.1021331","volume":"11","author":"AC Altamura","year":"2015","unstructured":"Altamura AC, Caldiroli A, Buoli M. Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders. Expert Opin Drug Metab Toxicol. 2015;11(4):649\u201360. https:\/\/doi.org\/10.1517\/17425255.2015.1021331.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1636_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab050","author":"D Seftel","year":"2021","unstructured":"Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of COVID-19. Open Forum Infect Dis. 2021. https:\/\/doi.org\/10.1093\/ofid\/ofab050.","journal-title":"Open Forum Infect Dis"},{"key":"1636_CR20","unstructured":"Together Clinical Trials [Website]. http:\/\/togethertrial.com. Accessed 3 Jun 2021."},{"key":"1636_CR21","doi-asserted-by":"publisher","unstructured":"Reis G, dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, Milagres AC, Santiago Ferreira T, et al. Effect of early treatment with Fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. Lancet Glob Health  2021;S2214-109X(21)00448-4. https:\/\/doi.org\/10.1016\/S2214-109X(21)00448-4.","DOI":"10.1016\/S2214-109X(21)00448-4"},{"issue":"2","key":"1636_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106044","volume":"56","author":"J Homolak","year":"2020","unstructured":"Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents. 2020;56(2): 106044. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106044.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1636_CR23","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.cell.2020.10.039","volume":"183","author":"S Ghosh","year":"2020","unstructured":"Ghosh S, Dellibovi-Ragheb TA, Kerviel A, et al. \u03b2-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell. 2020;183(6):1520-35.e14. https:\/\/doi.org\/10.1016\/j.cell.2020.10.039.","journal-title":"Cell"},{"issue":"8","key":"1636_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100142","volume":"1","author":"A Carpinteiro","year":"2020","unstructured":"Carpinteiro A, Edwards MJ, Hoffmann M, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1(8): 100142. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100142.","journal-title":"Cell Rep Med"},{"issue":"8","key":"1636_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023852","volume":"6","author":"J Kornhuber","year":"2011","unstructured":"Kornhuber J, Muehlbacher M, Trapp S, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS ONE. 2011;6(8): e23852. https:\/\/doi.org\/10.1371\/journal.pone.0023852.","journal-title":"PLoS ONE"},{"key":"1636_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.652688","volume":"12","author":"VP Sukhatme","year":"2021","unstructured":"Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12: 652688. https:\/\/doi.org\/10.3389\/fphar.2021.652688.","journal-title":"Front Pharmacol"},{"key":"1636_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-021-01326-z","author":"Y Hashimoto","year":"2021","unstructured":"Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci. 2021. https:\/\/doi.org\/10.1007\/s00406-021-01326-z.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"7","key":"1636_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","volume":"18","author":"RD Hays","year":"2009","unstructured":"Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873\u201380. https:\/\/doi.org\/10.1007\/s11136-009-9496-9.","journal-title":"Qual Life Res"},{"key":"1636_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection","year":"2020","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimum common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/S1473-3099(20)30483-7.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1636_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jval.2019.02.004","volume":"22","author":"D Cella","year":"2019","unstructured":"Cella D, Choi SW, Condon DM, Schalet B, Hays RD, Rothrock NE, et al. PROMIS\u00ae adult health profiles: efficient short-form measures of seven health domains. Value Health. 2019;22(5):537\u201344. https:\/\/doi.org\/10.1016\/j.jval.2019.02.004.","journal-title":"Value Health"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01636-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01636-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01636-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T07:07:22Z","timestamp":1644736042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01636-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1636"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01636-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"17 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This report was supported in part by a gift to the Keck School of Medicine of the University of Southern California by the W.M. Keck Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Reiersen and Dr. Lenze are listed on a patent application related to methods of treating COVID-19, that was filed by Washington University in St. Louis. No other authors report any conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"As this is a narrative review of available scientific evidence, all included data and material are available through the cited literature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SNF: Overall synthesis of material and first draft of manuscript; AMR, EJL, DRB: conceptualization, curatorship of data and findings; JDK: conceptualization, project leadership, and funding. All authors read and approved the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}